Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.57 |
| ▸ | BRAF | P15056 | 6/20 | 0.55 |
| ▸ | CSF1R | P07333 | 1/20 | 0.55 |
| ▸ | GRM5 | P41594 | 1/20 | 0.53 |
| ▸ | RAF1 | P04049 | 3/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | HPGDS | O60760 | 1/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.49 |
| ▸ | PLK1 | P53350 | 1/20 | 0.49 |
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
| ▸ | CCR8 | P51685 | 1/20 | 0.48 |
| ▸ | PYGL | P06737 | 1/20 | 0.48 |
| ▸ | PYGM | P11217 | 1/20 | 0.48 |
| ▸ | PLK4 | O00444 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14147364 | 0.87 | GRM5 (0.51) | KDRBRAFCSF1RGRM5GRM4 | |
| SCHEMBL110541 | 0.85 | GRM5 (0.52) | CSF1RGRM5GRM4CCR1CCR5 | |
| SCHEMBL19697440 | 0.84 | CSF1R (0.69) | KDRBRAFCSF1RRAF1MAPK14 | |
| SCHEMBL14527336 | 0.83 | NPC1 (0.58) | KDRBRAFCSF1RPLK4AURKA | |
| SCHEMBL14527291 | 0.82 | KDR (0.61) | KDRBRAFCSF1RRAF1EPHX2 | |
| SCHEMBL31175929 | 0.82 | CCR1 (0.52) | GRM5GRM4CCR1CCR5CCR8 | |
| SCHEMBL1703544 | 0.82 | CCR1 (0.52) | GRM5GRM4CCR1CCR5CCR8 | |
| SCHEMBL28292592 | 0.82 | KDR (0.53) | KDRBRAFCSF1RRAF1EPHX2 | |
| SCHEMBL3735813 | 0.81 | GRM5 (0.49) | CSF1RGRM5GRM4CCR1CCR5 | |
| SCHEMBL18681347 | 0.81 | BRAF (0.70) | KDRBRAFRAF1EPHX2PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| EP-4384510-A1 | COMPOUNDS TARGETING MUTANT OF P53 | Jacobio Pharmaceuticals Co., Ltd. (CN) | 2024-06-19 | — | — | EP | disclosed |
| CN-117813295-A | Compounds targeting p53 mutants | 北京加科思新药研发有限公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2023016434-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-02-16 | — | — | WO | disclosed |
| US-10597390-B2 | Indoles for use in influenza virus infection | JANSSEN SCIENCES IRELAND UC (IE) | 2020-03-24 | — | — | US | disclosed |
| EP-3013798-B1 | FUSED TRICYCLIC UREA COMPOUNDS AS RAF KINASE AND/OR RAF KINASE DIMER INHIBITORS | BEIGENE LTD (KY) | 2018-06-27 | — | — | EP | disclosed |
| WO-2017179926-A1 | NOVEL BENZOTHIOPHENE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF OR OPTICAL ISOMER THEREOF, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION, CONTAINING SAME AS ACTIVE INGREDIENT, FOR PREVENTING OR TREATING VIRAL DISEASE | 한국화학연구원 | 2017-10-19 | — | — | WO | disclosed |
| US-20170226102-A1 | INDOLES FOR USE IN INFLUENZA VIRUS INFECTION | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2017-08-10 | — | — | US | disclosed |
| US-20160318857-A1 | N,N'-Diarylurea Compounds and N,N'-Diarylthiourea Compounds as Inhibitors of Translation Initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-11-03 | — | — | US | disclosed |
| US-20160318857-A1 | N,N'-Diarylurea Compounds and N,N'-Diarylthiourea Compounds as Inhibitors of Translation Initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-11-03 | — | — | US | disclosed |
| CN-100422172-C | Substituted pyridines and pyridazines with angiogenesis inhibiting activity | BAYER PHARMACEUTICALS CORP (US) | 2008-10-01 | — | — | CN | disclosed |
| CN-100422173-C | Substituted pyridines and pyridazines with angiogenesis inhibiting activity | BAYER PHARMACEUTICALS CORP (US) | 2008-10-01 | — | — | CN | disclosed |
| CN-100374435-C | Substituted pyridazines having angiogenesis inhibiting activity | BAYER CORP (US) | 2008-03-12 | — | — | CN | disclosed |
| US-20070142440-A1 | Pyridinamide derivatives as kinase inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2007-06-21 | — | — | US | disclosed |
| US-20070142440-A1 | Pyridinamide derivatives as kinase inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2007-06-21 | — | — | US | disclosed |
| US-20070093529-A1 | Diacylhydrazine derivatives | MERCK PATENT GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093529-A1 | Diacylhydrazine derivatives | MERCK PATENT GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| CN-1769282-A | Substituted pyridines and pyridazines with angiogenesis inhibiting activity | BAYER PHARMACEUTICALS CORP (US) | 2006-05-10 | — | — | CN | disclosed |
| CN-1769283-A | Substituted pyridines and pyridazines with angiogenesis inhibiting activity | BAYER PHARMACEUTICALS CORP (US) | 2006-05-10 | — | — | CN | disclosed |
| CN-1420879-A | Substituted pyridines and pyridazines having angiogenesis inhibiting activity | BAYER AG (US) | 2003-05-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318857-A1 | N,N'-Diarylurea Compounds and N,N'-Diarylthiourea Compounds as Inhibitors of Translation Initiation | NSUN2, EIF2AK2, RNGTT | KDR 4697/4885BRAF 3879/4885CSF1R 4263/4885 |
| US-20070093529-A1 | Diacylhydrazine derivatives | BRAF, RAF1, NRAS | KDR 1543/4885BRAF 1/4885CSF1R 1858/4885 |
| US-10597390-B2 | Indoles for use in influenza virus infection | IDO1, IDO2, INMT | KDR 3158/4885BRAF 3074/4885CSF1R 838/4885 |
| US-20070142440-A1 | Pyridinamide derivatives as kinase inhibitors | TIE1, KDR, FLT1 | KDR 2/4885BRAF 49/4885CSF1R 449/4885 |
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | TP53, TP53BP1, MDM2 | KDR 1654/4885BRAF 257/4885CSF1R 3030/4885 |
| US-20170226102-A1 | INDOLES FOR USE IN INFLUENZA VIRUS INFECTION | IDO1, IDO2, INMT | KDR 3158/4885BRAF 3074/4885CSF1R 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.